We are live on ! Find out more
WIM

Woodford Investment Management Portfolio holdings

AUM $310M
1-Year Est. Return 17.41%
This Fund
S&P 500
This Quarter Est. Return
+26.57%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
+$345M
Cap. Flow
-$23.2M
Cap. Flow %
-0.94%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
3
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$44.6M
2
GILD icon
Gilead Sciences
GILD
+$39.5M
3
TBPH icon
Theravance Biopharma
TBPH
+$18.8M
4
ALKS icon
Alkermes
ALKS
+$642K

Top Sells

Rank Stock Value
1
RAI
Reynolds American Inc
RAI
+$86M
2
ABBV icon
AbbVie
ABBV
+$40.6M
3
PRTA icon
Prothena Corp
PRTA
+$161K

Sector Composition

Rank Sector Weight
1 Healthcare 85.5%
2 Consumer Staples 14.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$435B
$696M 28.12%
11,029,800
-627,000
-5% -$40.6M
PRTA icon
2
Prothena Corp
PRTA
$450M
$617M 24.96%
10,301,751
-3,000
-0% -$161K
RAI
3
DELISTED
Reynolds American Inc
RAI
$359M 14.5%
7,608,324
-1,714,139
-18% -$86M
ALKS icon
4
Alkermes
ALKS
$8.25B
$355M 14.35%
7,549,033
+13,500
+0.2% +$642K
TBPH icon
5
Theravance Biopharma
TBPH
$877M
$341M 13.78%
9,407,137
+673,500
+8% +$18.8M
BIIB icon
6
Biogen
BIIB
$30.7B
$53.4M 2.16%
170,430
+150,430
+752% +$44.6M
GILD icon
7
Gilead Sciences
GILD
$165B
$38.5M 1.56%
+486,800
New +$39.5M
NWBO
8
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$14.1M 0.57%
25,915,937
– –

Similar funds

LCM
Lucha Capital Management San Francisco, California $327M AUM 2.87% 1-Year Est. Return
GWA
Guidant Wealth Advisors Palatine, Illinois $269M AUM 2.79% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
AEPG
American Economic Planning Group Warren, New Jersey $367M AUM 2.51% 1-Year Est. Return
AR
Argyll Research Wilmington, Delaware $377M AUM 4.86% 1-Year Est. Return
KCM
Keywise Capital Management Grand Cayman, Cayman Islands $220M AUM 21.27% 1-Year Est. Return
COI
Capital One Investing Mclean, Virginia $430M AUM 3.49% 1-Year Est. Return

Woodford Investment Management's Q3 2016 Portfolio in Review

As of Q3 2016, Woodford Investment Management held 8 positions worth $2.47B, up 16% from $2.13B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Woodford Investment Management's Q3 2016 filing shows 1 new, 3 increased and 3 reduced positions. Its largest new stake was Gilead Sciences: 486,800 shares worth $38.5M. The largest sale was Reynolds American Inc, an estimated $86M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 76% a quarter earlier, followed by Consumer Staples.

  • Woodford Investment Management's largest Q3 2016 buy was Gilead Sciences: 486,800 shares worth $38.5M.
  • Woodford Investment Management added most to Biogen in Q3 2016, an estimated $44.6M increase.
  • Woodford Investment Management's biggest Q3 2016 reduction was Reynolds American Inc, cutting an estimated $86M.
  • Woodford Investment Management's ten largest holdings make up 100% of its $2.47B portfolio in Q3 2016.
  • Woodford Investment Management opened 1 new position and closed 0 in Q3 2016.
  • Woodford Investment Management's portfolio value rose 16% quarter-over-quarter to $2.47B.

Based on Woodford Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.